Breast Cancer Chemotherapy: — How It Works, Cycles & What to Expect

Chemotherapy uses cell-killing medicines that travel through the bloodstream to reach cancer cells anywhere in the body. Because it is a systemic treatment, it can destroy cancer cells that may have spread beyond the breast — including cells too small to see on a scan — which surgery and radiation cannot do. In breast cancer it is used before surgery to shrink a tumour, after surgery to lower the chance of the cancer returning, or to control advanced disease. It targets rapidly dividing cells, which is why it works against cancer but also causes temporary side effects such as hair loss and low blood counts. Whether you need it depends on your subtype, stage and grade.

Both use the same kinds of medicines — the difference is the timing. Neoadjuvant chemotherapy is given before surgery. It shrinks the tumour (sometimes enough to allow breast-conserving surgery instead of mastectomy) and lets the team see how well the cancer responds, which guides later treatment. It is standard for most triple-negative and HER2-positive cancers. Adjuvant chemotherapy is given after surgery to destroy any cancer cells that may remain and reduce the risk of recurrence; it is common when the tumour was larger, the lymph nodes were involved, or the biology suggests higher risk. Your tumour board decides which order is best for your specific cancer.

Chemotherapy is given in cycles — each a treatment day (or days) followed by a rest period that lets healthy cells recover. Most breast cancer plans run between 4 and 8 cycles, spread across roughly 12 to 24 weeks, though this varies with the regimen chosen for your subtype and stage. Some plans use "dose-dense" scheduling, giving cycles every 2 weeks instead of 3 with growth-factor support, for certain higher-risk cancers. Many plans also run in two phases, using one group of medicines first and a different group next. Doses and timing can be adjusted based on your blood counts and how you tolerate treatment — delaying a cycle to recover is common and safe.

No. One of the most important jobs of a good oncology team is deciding who truly benefits — and sparing those who do not from unnecessary side effects. Triple-negative and HER2-positive cancers almost always need chemotherapy, and it is added for higher-risk hormone-positive cancers (larger tumours, node-positive, high-grade). But many small, low-grade, node-negative hormone-positive cancers do very well with surgery and hormone therapy alone. Gene-expression tests can confirm when chemotherapy can be safely skipped without raising the risk of recurrence. At CION, the decision to give — or safely avoid — chemotherapy is made by a tumour board on evidence, not habit.

The common side effects are tiredness, nausea, hair thinning or loss, mouth soreness, and low blood counts, which can raise infection risk. Most are temporary and resolve after treatment ends — hair, for example, usually regrows. Modern supportive care has made chemotherapy far easier to tolerate than in the past: anti-nausea medicines, growth factors to protect blood counts, scalp cooling to reduce hair loss, and good nutrition all help. Our team manages side effects actively rather than asking you to simply endure them. You can read our detailed guides on chemotherapy side effects, hair loss and diet during chemotherapy for practical, day-to-day advice.

Chemotherapy can affect fertility, sometimes temporarily and sometimes permanently, depending on the drugs used and your age. This is why fertility should be discussed before treatment starts, not after — especially for younger women. Options such as egg or embryo freezing, and medicines to help protect the ovaries during chemo, may be possible if planned in advance. Many women do go on to have children after breast cancer treatment, but the conversation needs to happen early. At CION, we raise fertility preservation up front for younger patients and connect you with the right specialists. See our pages on chemotherapy and fertility and fertility preservation for more detail.

The cost varies widely with the regimen, the number of cycles, the subtype, and whether targeted or immune drugs are added. As a broad, indicative range only, a full course of standard chemotherapy often falls around ₹1–4 lakh, while plans that include HER2-targeted therapy can be considerably higher. Your actual cost depends on your specific plan, your centre and your insurance, so treat any figure as an estimate. Most health insurance policies cover cancer chemotherapy, and eligible patients in Telangana and Andhra Pradesh may be covered under schemes such as Aarogyasri or Ayushman Bharat. CION discusses likely costs up front, offers up to 50% discounts on diagnostics, and helps with insurance paperwork.

Yes. CION offers a free first consultation for all cancer patients, including women who have been told they need chemotherapy or want a second opinion before starting. It is a full 45-minute consultation — a specialist reviews your biopsy and reports, confirms whether chemotherapy is genuinely needed for your subtype and stage, and explains the right regimen, order and duration. Because the plan is reviewed by a tumour board, you can be confident you are not receiving chemotherapy you do not need. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.